Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of bifidobacterium lactis tci604 and its metabolites

A TCI604, Bifidobacterium lactis technology, applied in the direction of bifidobacteria, applications, metabolic diseases, etc., can solve problems such as complications and patient disease recurrence

Active Publication Date: 2022-05-27
TCI CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When necessary, drugs (such as antacids, blood lipid-lowering drugs) will be used clinically to relieve the patient's discomfort, but only a temporary effect can be achieved; and if the treatment is performed by surgery, the patient still has to face disease recurrence, and risks of complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium lactis tci604 and its metabolites
  • Application of bifidobacterium lactis tci604 and its metabolites
  • Application of bifidobacterium lactis tci604 and its metabolites

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1: Protease activity detection test of Bifidobacterium lactis TCI604

[0054] The cryopreservation tube containing the Bifidobacterium lactis TCI604 strain of [Preparation Example A-3] was thawed, and the TCI604 strain was inoculated into an MRS medium (BDTMDifcoTM Lactobacilli MRS Broth) and cultured at 37°C to activate the strain . Next, take a piece of Skim milk agar and dig a hole in it. Then, 50 microliters of the once activated TCI604 strain was injected into the holes on the aforementioned agar and incubated at 37°C for 24 hours. Finally, observe whether a transparent ring is produced on the cultured agar (if a transparent ring is produced, it means that the cultured strain has protease activity), and take pictures to record. Results are shown in figure 1 .

[0055] Depend on figure 1 It can be seen that Bifidobacterium lactis TCI604 of the present invention can form a transparent ring on skim milk agar. The aforementioned results show that the Bifi...

Embodiment 2

[0056] Example 2: Gastric acid resistance and bile salt resistance test of Bifidobacterium lactis TCI604

[0057] The cryopreservation tube containing the Bifidobacterium lactis TCI604 strain of [Preparation Example A-3] was thawed, and the TCI604 strain was inoculated into an MRS medium (BDTMDifcoTM Lactobacilli MRS Broth) and cultured at 37°C to activate the strain . The activated TCI604 strain was then rinsed twice with 1x phosphate-buffered saline (Phosphate-bufferedsaline, PBS), and then re-dissolved with 0.3 ml of PBS (total bacterial count was about 1x10 10 ). Divide the lysate after the aforementioned treatment into three groups (each group contains 0.1 ml of the lysate), and add each group of lysates to the following solutions:

[0058] 1. Control group: 99 ml of 0.2M KCl solution (pH 7).

[0059] 2. Gastric acid group: 99 ml of 0.2M KCl solution (pH 1.2).

[0060] 3. Bile salt group: 99 ml of 0.2M KCl solution (containing 0.3% bile salt).

[0061] Next, the solu...

Embodiment 3

[0063] Example 3: Intestinal colonization effect test of Bifidobacterium lactis TCI604

[0064] (3-1) The human colon adenocarcinoma cell line Caco-2 was cultured in a triangular dish (T75Flask) for 120 hours. Next, the culture medium was removed, and after rinsing the cells twice with 1x PBS, 1 ml of 1% trypsin (Trypsin / EDTA) was added to suspend the cells. The aforementioned cell suspension was injected into a 24-well plate (4 × 10 5 cells / well) at 37°C, 5% CO 2 Incubate overnight. After that, after rinsing the cells twice with 1×PBS, 900 μl of fresh antibiotic-free culture medium was added to each well.

[0065](3-2) Thaw the cryopreservation tube containing the Bifidobacterium lactis TCI604 strain of [Preparation Example A-3], inoculate the TCI604 strain into MRS medium (BDTMDifcoTMLactobacilli MRS Broth) and culture at 37°C, to activate the strain. The activated TCI604 strain was then rinsed twice with 1x PBS, and then re-solubilized with 1x PBS (total bacterial coun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Bifidobacterium lactis (Bifidobacterium lactis) TCI604 and applications of the Bifidobacterium lactis TCI604 and its metabolites, wherein the Bifidobacterium lactis TCI604 is deposited in the German Culture Collection of Microorganisms (the deposit number is DSM33303), and the Bifidobacterium lactis Bacillus TCI604 and its metabolites have the effect of regulating CRP, IL-1β, IL8, IL6, IL10, IL17A, TNF-α, CYP7A1, and APC gene expression, so it can be used to reduce the incidence of colorectal polyps, reduce the incidence of colorectal cancer, reduce The incidence of peptic ulcer, reduce the incidence of gastroesophageal reflux, help digestion, improve gastrointestinal function, regulate immunity, and regulate blood lipids.

Description

technical field [0001] The present invention relates to a novel Bifidobacterium lactis (Bifidobacterium lactis, also known as Reitia bifidii) TCI604 (deposited in the German Collection of Microorganisms, the deposit number is DSM33303) and the application of its metabolites, especially It is about the application of the aforementioned Bifidobacterium lactis TCI604 and its metabolites in at least one of the following: reducing the incidence of colorectal polyps, reducing the incidence of colorectal cancer, reducing the incidence of peptic ulcer, reducing the incidence of gastroesophageal reflux, helping digestion, Improve gastrointestinal function, regulate immunity, regulate blood lipids, regulate CRP gene expression, regulate IL-1β gene expression, regulate IL8 gene expression, regulate IL6 gene expression, regulate IL10 gene expression, regulate IL17A gene expression, regulate TNF-α gene expression, regulate CYP7A1 gene expression, and regulation of APC gene expression. Ba...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20A23L33/135A61K35/745A61P35/00A61P1/04A61P1/00A61P1/14A61P3/06A61P37/02C12R1/01
CPCC12N1/20A23L33/135A61K35/745A61P35/00A61P1/04A61P1/00A61P1/14A61P3/06A61P37/02A23V2002/00C12R2001/01C12N1/205A23V2400/531A23V2200/3204A23V2200/324A23V2200/3262
Inventor 林咏翔
Owner TCI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com